Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer,
today announced the hosting of an Investor Symposium on June 3,
2016 at BioNua, its veterinary biologics manufacturing facility in
Tullamore, Ireland. The event marks the official opening of the
facility and will coincide with a Biopharma Showcase co-organised
by the Irish Government agencies Enterprise Ireland and IDA
Ireland, which will occur on June 2, 2016 at the National Institute
for Bioprocessing Research and Training (NIBRT).
A focal point of Nexvet’s Investor Symposium at BioNua will be
the emerging field of therapeutic veterinary biologics and BioNua’s
growing manufacturing capabilities in this area. The Irish
Biopharma Showcase is intended to provide an overview of the
biopharmaceutical industry in Ireland, while facilitating
connectivity between institutional investors and several of
Ireland’s established and emerging biopharmaceutical companies.
"The compelling advantages of biologic therapies for chronic
conditions in companion animals underpin Nexvet’s long-term vision
for transforming animal medicine. Managing in-house manufacturing
of our therapies in development is a key part of Nexvet’s strategy
to become a vertically integrated leader in veterinary
biopharmaceuticals. As we approach an operational milestone for
BioNua, we are hosting this event so investors may better
understand the opportunity in veterinary biopharmaceuticals, and
the value we are creating through investing in manufacturing and
specifically, in Ireland,” said Dr. Mark Heffernan, Chief Executive
Officer of Nexvet.
BioNua is a wholly owned subsidiary comprising a 20,000 square
foot facility in Tullamore, Ireland. This site was previously
devoted to producing human biopharmaceuticals prior to the Company
securing the facility in September, 2015. The facility historically
operated under an Investigational Medicinal Products and cGMP
Manufacturing licenses from Ireland's Health Products Regulatory
Authority and is equipped with cGMP grade clean rooms, water for
injection, purified water, and clean steam generation systems. In
addition, the facility is equipped with analytical and development
laboratories. Nexvet is reconfiguring the facility to be a
dedicated veterinary biopharmaceutical facility using
state-of-the-art disposable bioreactors, with the capability to
meet the Company’s anticipated future clinical and commercial
production needs for therapeutic drug substance.
To register for Nexvet’s Investor Symposium on June 3 and/or the
Irish Biopharma Showcase on June 2, please RSVP by May 20, 2016 to
IR@nexvet.com with your name, company and phone number.
Detailed agendas will be distributed prior to both events.
About Nexvet
(www.nexvet.com)
Nexvet is a veterinary biologics developer focused on
transforming the therapeutic market for companion animals, such as
dogs and cats, by developing and commercializing novel,
species-specific biologics. Nexvet’s proprietary PETization™
platform is designed to rapidly design monoclonal antibodies (mAbs)
that are recognized as “self” or “native” by an animal’s immune
system, a property Nexvet refers to as “100% species-specificity.”
Nexvet’s product candidates also build upon the safety and efficacy
data from clinically tested human therapies, thereby reducing
clinical risk and development cost.
Nexvet is leveraging diverse global expertise and incentives to
build a vertically integrated biopharmaceutical company, which
conducts drug discovery in Australia, conducts clinical
development in the United States and Europe and is
growing its biomanufacturing capabilities in Ireland.
Further information:
Investors
Candice
Knoll
Blueprint Life Science
Group
+1 415-375-3340 Ext.
4
cknoll@bplifescience.com
MediaJessica BurnsBerry & Company Public
Relations+1 212-253-8881jburns@berrypr.com
IDA IrelandJayne Wyatt+353 1 603
4232jayne.wyatt@ida.ie
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements consist of all statements other
than statements of historical fact, including statements regarding
our future results of operations and financial position, results of
any current or future pivotal safety and efficacy study, future
expenditures relating to our lead product candidates, time for
completion of any of our studies or facilities updates, ability to
develop our pipeline of product candidates, business strategy,
prospective products, ability to successfully manufacture our own
product candidates, ability to meet conditions for the receipt of
government grants, ability to qualify for conditional licensure or
obtain product approvals, research and development costs, timing
and likelihood of success, plans and objectives of management for
future operations, and future results of current and anticipated
products. These statements relate to future events or to our future
financial performance and involve known and unknown risks,
uncertainties and other factors which may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. The words “anticipate,”
“assume,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “might,” “objective,” “plan,” “potential,”
“predict,” “project,” “position,” “seek,” “should,” “target,”
“will,” “would,” or the negative of these terms or other similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements are based
on current expectations, estimates, forecasts and projections about
our business and the industry in which we operate, and management’s
beliefs and assumptions are not guarantees of future performance or
development and involve known and unknown risks, uncertainties and
other factors.
Factors that could cause actual results to differ materially
from our expectations expressed in this report include those
summarized under Risk Factors in our reports on Forms 10-Q and 10-K
and the other documents we file from time to time with the
Securities and Exchange Commission. Given these risks and
uncertainties, you should not place undue reliance on these
forward-looking statements. Also, forward-looking statements
represent management’s beliefs and assumptions only as of the date
of this press release. Except as required by law, we do not intend,
and undertake no obligation, to revise or update these
forward-looking statements, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future.
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Jun 2024 to Jul 2024
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Jul 2023 to Jul 2024